Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Nov 18;5:16214. doi: 10.1038/srep16214

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2015, Macmillan Publishers Limited

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

(a) T1-weighted spin echo MR imaging of ProCA1.GRPR targeting GRPR in PC3 (red arrow) and H441 (blue arrow) xenografted mice tumors. (b) T1-weighted spin echo MR imaging of non-targeted ProCA1 in PC3 (red arrow) and H441 (blue arrow) xenografted mice tumors. (c) Percentage of increase in MRI signal in PC3 and H441 tumor before and after injection of ProCA1.GRPR. PC3 tumor exhibits a 1.5 fold higher MRI enhancement compared with H441 tumor at 48 hours post injection of ProCA1.GRPR. (d) Percentage of MRI signal increase in PC3 and H441 tumor before and after injection of non-targeted ProCA1. As a negative control, non-targeted ProCA1 does not have significant enhancement in both tumors after injection of non-targeted ProCA1. Images a-d are representatives of three independent experiments. Data are expressed as mean ± s.d. of percentage increase of tumor intensity values measured from different MRI slides of H441 or PC3 tumor in each representative animal from three independent experiments. (e, f) MRI shows heterogeneous enhancement in PC3 (e) and H441 tumors (f) after injection of ProCA1.GRPR. (g) NIR imaging of PC3 and H441 xenografted mice tumors 48 hours post ProCA1.GRPR injection. (h) NIR imaging of isolated PC3, H441 tumors and muscle 48 h post injection of ProCA1.GRPR. PC3 tumor shows higher NIR intensity compared to H441 tumor. (i) Gd³⁺ distribution in different tissues 48 hours post ProCA1.GRPR injection. Data are expressed as mean ± s.d.